NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma

Purpose: Only one chemical class of topoisomerase I (TOP1) inhibitors is FDA approved, the camptothecins with irinotecan and topotecan widely used. Because of their limitations (chemical instability, drug efflux-mediated resistance, and diarrhea), novel TOP1 inhibitors are warranted. Indenoisoquinoline non-camptothecin topoisomerase I (TOP1) inhibitors overcome chemical instability and drug resistance that limit camptothecin use. Three indenoisoquinolines, LMP400 (indotecan), LMP776 (indimitecan), and LMP744, were examined in a phase I study for lymphoma-bearing dogs to evaluate differential efficacy, pharmacodynamics, toxicology, and pharmacokinetics. Experimental Design: Eighty-four client-owned dogs with lymphomas were enrolled in dose-escalation cohorts for each indenoisoquinoline, with an expansion phase for LMP744. Efficacy, tolerability, pharmacokinetics, and target engagement were determined. Results: The MTDs were 17.5 mg/m2 for LMP 776 and 100 mg/m2 for LMP744; bone marrow toxicity was dose-limiting; up to 65 mg/m2 LMP400 was well-tolerated and MTD was not reached. None of the drugs induced notable diarrhea. Sustained tumor accumulation was observed for LMP744; γH2AX induction was demonstrated in tumors 2 and 6 hours after treatment; a decrease in TOP1 protein was observed in most lymphoma samples across all compounds and dose levels, which is consistent with the fact that tumor response was also observed at low doses LMP744. Objective responses were documented for all indenoisoquinolines; efficacy (13/19 dogs) was greatest for LMP744. Conclusions: These results demonstrate proof-of-mechanism for indenoisoquinoline TOP1 inhibitors supporting their further clinical development. They also highlight the value of the NCI Comparative Oncology Program (https://ccr.cancer.gov/Comparative-Oncology-Program) for evaluating novel therapies in immunocompetent pets with cancers.

[1]  Y. Pommier,et al.  Roles of eukaryotic topoisomerases in transcription, replication and genomic stability , 2016, Nature Reviews Molecular Cell Biology.

[2]  K. Kohn,et al.  Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. , 1989, Cancer research.

[3]  Edmund E. Kim,et al.  Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Y. Cheng,et al.  Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. , 1995, Molecular pharmacology.

[5]  Yves Pommier,et al.  γH2AX and cancer , 2008, Nature Reviews Cancer.

[6]  C. Khanna,et al.  Defining the Value of a Comparative Approach to Cancer Drug Development , 2015, Clinical Cancer Research.

[7]  Y. Pommier,et al.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives , 2009, Molecular Cancer Therapeutics.

[8]  Y. Pommier,et al.  Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762. , 2012, Cancer research.

[9]  James H. Doroshow,et al.  Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers , 2010, Clinical Cancer Research.

[10]  M. Paoloni,et al.  The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Cancer Drug Development Pathway , 2009, PLoS medicine.

[11]  Y. Pommier,et al.  Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I Poison , 2005, Molecular Pharmacology.

[12]  Yvonne A. Evrard,et al.  Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity , 2010, Clinical Cancer Research.

[13]  S. Libutti,et al.  Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNFα to Cancer Vasculature , 2009, PloS one.

[14]  Y. Pommier,et al.  Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. , 2007, Cancer research.

[15]  E. Cvitkovic,et al.  Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. , 1996, European journal of cancer.

[16]  M. Gore,et al.  Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Yves Pommier,et al.  Interfacial inhibitors: targeting macromolecular complexes , 2012, Nature Reviews Drug Discovery.

[18]  Y. Pommier,et al.  Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. , 1998, Molecular pharmacology.

[19]  J. Champoux,et al.  Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. , 1998, Science.

[20]  Y. Pommier,et al.  Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors , 2016, Cancer Chemotherapy and Pharmacology.

[21]  W. Reinhold,et al.  Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity , 2009, Molecular Cancer Therapeutics.

[22]  Lance Stewart,et al.  The mechanism of topoisomerase I poisoning by a camptothecin analog , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Mark Dewhirst,et al.  Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology , 2016, Science Translational Medicine.

[24]  T. Burke,et al.  The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. , 1994, Journal of medicinal chemistry.

[25]  C. Khanna,et al.  Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document. , 2010, Veterinary and comparative oncology.

[26]  L. Siu,et al.  A Risk-Benefit Assessment of Irinotecan in Solid Tumours , 1998, Drug safety.

[27]  Y. Pommier,et al.  ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. , 2014, Cancer research.

[28]  K. Kohn,et al.  Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. , 2003, Cancer research.

[29]  J. Doroshow,et al.  Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug—induced DNA double strand breaks from DNA double strand breaks associated with apoptosis , 2018, Oncotarget.

[30]  Y. Pommier,et al.  Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. , 1999, Cancer research.

[31]  Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. , 2016, Veterinary and comparative oncology.

[32]  L. Grochow,et al.  Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  K. Kohn,et al.  Death Receptor-Induced Activation of the Chk2- and Histone H2AX-Associated DNA Damage Response Pathways , 2008, Molecular and Cellular Biology.